First-line treatment options for extensive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests different drug combinations for extensive-stage small cell lung cancer, tailored to the cancer's biomarkers. It aims to find which treatment works best for patients newly diagnosed or whose cancer returns after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed as small cell lung cancer and spread beyond one lung or to other parts of the body.
- You have not had any prior treatment for advanced cancer, or you had treatment for a localized cancer that has come back.
- Your doctor expects you to live at least 3 months.
- You have at least one tumor that can be measured and has not been treated with radiation.
- Your overall physical condition is good (able to do daily activities without serious limitations).
- Your blood counts and organ functions (liver, kidney, etc.) are adequate.
- You do not have uncontrolled high blood pressure, serious heart problems, or recent heart events.
- You have not had other cancers within the last 2 years (except certain non-melanoma skin cancers or early-stage cancers).
- You do not have an active infection like hepatitis B, C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new combination therapy for extensive-stage small cell lung cancer (cancer that has spread beyond the lung). The treatment includes an immunotherapy drug, a drug that blocks blood vessel growth to tumors, and chemotherapy. It aims to see how well this combination works in people who have not yet been treated for this cancer.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests different experimental drugs matched to the specific genetic makeup of your small cell lung cancer. The goal is to see if targeting your cancer's particular molecular type can shrink tumors or delay their growth better than standard care.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Hear when a new Extensive Stage Lung Small Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.